DB:OC9

Stock Analysis Report

Executive Summary

Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide.


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Omnicell's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OC9 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.0%

OC9

3.0%

DE Healthcare Services

0.5%

DE Market


1 Year Return

35.7%

OC9

31.9%

DE Healthcare Services

15.5%

DE Market

Return vs Industry: OC9 exceeded the German Healthcare Services industry which returned 33.4% over the past year.

Return vs Market: OC9 exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

OC9IndustryMarket
7 Day4.0%3.0%0.5%
30 Day6.1%1.1%1.4%
90 Day18.2%10.8%5.3%
1 Year35.7%35.7%33.1%31.9%19.2%15.5%
3 Year148.1%148.1%69.8%65.4%15.7%5.5%
5 Year176.7%176.7%180.9%168.5%27.3%10.1%

Price Volatility Vs. Market

How volatile is Omnicell's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Omnicell undervalued compared to its fair value and its price relative to the market?

3.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OC9 (€74) is trading below our estimate of fair value (€79.97)

Significantly Below Fair Value: OC9 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: OC9 is poor value based on its PE Ratio (63.2x) compared to the Healthcare Services industry average (12.7x).

PE vs Market: OC9 is poor value based on its PE Ratio (63.2x) compared to the German market (20.6x).


Price to Earnings Growth Ratio

PEG Ratio: OC9 is poor value based on its PEG Ratio (2.3x)


Price to Book Ratio

PB vs Industry: OC9 is overvalued based on its PB Ratio (4.3x) compared to the DE Healthcare Services industry average (2.6x).


Next Steps

Future Growth

How is Omnicell forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

27.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OC9's forecast earnings growth (27.7% per year) is above the savings rate (-0.4%).

Earnings vs Market: OC9's earnings (27.7% per year) are forecast to grow faster than the German market (13.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: OC9's revenue (11.1% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: OC9's revenue (11.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OC9's Return on Equity is forecast to be low in 3 years time (8.3%).


Next Steps

Past Performance

How has Omnicell performed over the past 5 years?

14.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OC9 has high quality earnings.

Growing Profit Margin: OC9's current net profit margins (6.3%) are lower than last year (7%).


Past Earnings Growth Analysis

Earnings Trend: OC9's earnings have grown by 14.8% per year over the past 5 years.

Accelerating Growth: OC9's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: OC9 had negative earnings growth (-0.2%) over the past year, making it difficult to compare to the Healthcare Services industry average (27.6%).


Return on Equity

High ROE: OC9's Return on Equity (6.7%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Omnicell's financial position?


Financial Position Analysis

Short Term Liabilities: OC9's short term assets ($477.1M) exceed its short term liabilities ($228.2M).

Long Term Liabilities: OC9's short term assets ($477.1M) exceed its long term liabilities ($208.6M).


Debt to Equity History and Analysis

Debt Level: OC9's debt to equity ratio (9.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if OC9's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: OC9's debt is well covered by operating cash flow (204.4%).

Interest Coverage: OC9's interest payments on its debt are well covered by EBIT (11.4x coverage).


Balance Sheet

Inventory Level: OC9 has a low level of unsold assets or inventory.

Debt Coverage by Assets: OC9's debt is covered by short term assets (assets are 6.2x debt).


Next Steps

Dividend

What is Omnicell's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OC9's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OC9's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OC9's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OC9's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OC9's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Omnicell's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Randy Lipps (62yo)

17.3yrs

Tenure

US$6,335,581

Compensation

Mr. Randall A. Lipps, also known as Randy, founded Omnicell, Inc. in September 1992 and has been its Chief Executive Officer and President since October 2002. Mr. Lipps had been Executive Chairman and Exec ...


CEO Compensation Analysis

Compensation vs Market: Randy's total compensation ($USD6.34M) is above average for companies of similar size in the German market ($USD2.07M).

Compensation vs Earnings: Randy's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

3.3yrs

Average Tenure

55yo

Average Age

Experienced Management: OC9's management team is considered experienced (3.3 years average tenure).


Board Age and Tenure

6.5yrs

Average Tenure

63yo

Average Age

Experienced Board: OC9's board of directors are considered experienced (6.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sell€461,21631 May 19
Joseph Spears
EntityIndividual
Role
Chief Accounting Officer
Chief Accounting Officer
Shares6,450
Max Price€71.56
Sell€276,90915 May 19
Joanne Bauer
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,798
Max Price€72.91
Sell€81,88208 May 19
Peter Kuipers
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares1,114
Max Price€73.50
Sell€83,91412 Mar 19
Jorge Taborga
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Engineering & Integration Management Officer
Shares1,132
Max Price€74.13
Sell€213,31004 Mar 19
Joseph Spears
EntityIndividual
Role
Chief Accounting Officer
Chief Accounting Officer
Shares2,846
Max Price€74.95
Sell€1,508,66722 Feb 19
Randall Lipps
EntityIndividual
Role
Chief Executive Officer
Founder
Shares20,000
Max Price€75.70
Sell€72,96216 Feb 19
Gary Petersmeyer
EntityIndividual
Shares1,000
Max Price€72.96
Sell€52,27512 Feb 19
Gary Petersmeyer
EntityIndividual
Shares750
Max Price€69.70

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.


Management Team

  • Randy Lipps (62yo)

    Founder

    • Tenure: 17.3yrs
    • Compensation: US$6.34m
  • Dan Johnston (55yo)

    Executive VP

    • Tenure: 4.9yrs
    • Compensation: US$1.16m
  • Scott Seidelmann (43yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 1.8yrs
    • Compensation: US$2.40m
  • Nhat Ngo (46yo)

    Executive VP of Marketing

    • Tenure: 7.8yrs
    • Compensation: US$2.02m
  • Susan Moriconi

    Chief Human Resources Officer

    • Tenure: 0.3yrs
  • Jorge Taborga (60yo)

    Executive Vice President of Engineering & Integration Management Officer

    • Tenure: 12.5yrs
  • Peter Kuipers (47yo)

    Executive VP & CFO

    • Tenure: 4.4yrs
    • Compensation: US$2.47m
  • Joe Spears (59yo)

    Chief Accounting Officer

    • Tenure: 2.3yrs
  • Giri Chodavarapu

    Chief Information Officer

    • Tenure: 0.3yrs
  • Niloy Sanyal

    Chief Marketing Officer

    • Tenure: 0.3yrs

Board Members

  • Jim Judson (64yo)

    Lead Independent Director

    • Compensation: US$286.21k
  • Randy Lipps (62yo)

    Founder

    • Tenure: 17.3yrs
    • Compensation: US$6.34m
  • Mark Parrish (63yo)

    Independent Director

    • Tenure: 7yrs
    • Compensation: US$224.95k
  • Sara White (73yo)

    Independent Director

    • Tenure: 16.8yrs
    • Compensation: US$251.97k
  • Rob Seim (59yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$2.65m
  • Joanne Bauer (63yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$231.22k
  • Vance Moore (58yo)

    Independent Director

    • Tenure: 7.7yrs
    • Compensation: US$229.97k
  • Bruce Scott (63yo)

    Independent Director

    • Tenure: 0.7yrs
  • Bruce Smith (71yo)

    Independent Director

    • Tenure: 5.7yrs
    • Compensation: US$224.95k

Company Information

Omnicell, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Omnicell, Inc.
  • Ticker: OC9
  • Exchange: DB
  • Founded: 1992
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$3.648b
  • Listing Market Cap: US$3.290b
  • Shares outstanding: 41.94m
  • Website: https://www.omnicell.com

Number of Employees


Location

  • Omnicell, Inc.
  • 590 East Middlefield Road
  • Mountain View
  • California
  • 94043
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OMCLNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2001
OC9DB (Deutsche Boerse AG)YesCommon StockDEEURAug 2001

Biography

Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility’s in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/22 21:41
End of Day Share Price2020/01/22 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.